Compare Marvell Technology Inc (MRVL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs TransMedics Group Inc — how do they compare? Marvell Technology Inc trades at $210.36 (market cap $171.11B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Marvell Technology Inc is far larger — about 67.4× TransMedics Group Inc's market cap, and Marvell Technology Inc pays a 0.12% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MRVL | TMDX | |
|---|---|---|
Market Cap | $171.11B | $2.54B |
Sector | Technology | Technology |
52-Week High | $316.43 | $150.42 |
52-Week Low | $62.31 | $61.99 |
Enterprise Value | $172.55B | $2.94B |
Dividend Yield | 0.12% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
